Catalyst Calendar

Thu, Sep 24, 2026

1 updates

7:17 PM

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no additional treatment for diabetic retinopathy No IOI observed with short-course prophylactic topical

Presentation / Abstract • Phase 2Retina Society presentation Thu, Sep 24, 2026, EDTregenxbio.com

Tue, Sep 8, 2026

1 updates

RGNX

7:05 AM

REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., Sept. 8, 2026 / PRNewswire / -- REGENXBIO Inc. ( Nasdaq: RGNX) today announced it will participate in the following investor conferences: Baird 2026 Global Healthcare Conference Fireside Chat: Tuesday, September 15 at 8:30 a.m. ET Location: New York, NY Morgan Stanley 24th Annual

regenxbio.com

Tue, Aug 25, 2026

1 updates

RGNX

7:05 AM

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming catalysts across its late-stage pipeline of potential first-and best-in-class gene therapies, Mr.

regenxbio.com

Mon, Aug 24, 2026

1 updates

RGNX

7:05 AM

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

ROCKVILLE, Md., Aug. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome. The U.S.

regenxbio.com